VANCOUVER, British Columbia--(BUSINESS WIRE)-- ProtoKinetix (OTCBB: PKTX) (www.protokinetix.com), announces today that it has completed the sale of (AAGP™) as a vital tool to protect delicate cells in the process of utilizing stem cells, to treat disease and injury. This development will enable the Company to ramp up sales of the unique AAGP™ family of molecules to the medical research community. This community includes major pharmaceutical corporations, universities, foundations, private laboratories, and government agencies.
Due to the extremely delicate nature and high cost of producing cells typically used in medical research, the protection and defense of these cells is a critical priority in any successful research program. AAGP™ has demonstrated superior properties of protection in the face of a wide range of hostilities. Data shows that the addition of this family of molecules will substantially increase the viability and longevity of these critical cells, resulting in a cost reducing, shorter research cycle.
Whilst the primary focus of ProtoKinetix internally is the development of disease specific therapeutic agents, this opportunity to commence cash flow will enhance the Company’s ability to expand its therapeutic targets.
About ProtoKinetix
ProtoKinetix, Inc. is a biotechnology company that has developed and patented a family of synthetic anti-aging glycopeptides (AAGP™) for medicine and the biotechnology and cosmetic industries. PKTX’s primary focus is on the therapeutic potential for AAGP™ in the treatment of Diabetes, inflammatory diseases, skin protection and anti-aging.
The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission.
Ross L. Senior – President and CEO
CONTACT:
ProtoKinetix Inc.
Blair Henderson
604-926-6627
KEYWORDS: United States North America Canada
INDUSTRY KEYWORDS: Technology Nanotechnology Health Biotechnology Public Policy/Government Healthcare Reform Homeland Security Other Policy Issues State/Local Philanthropy Research Other Science Science Foundation General Health
MEDIA:
| Logo |